Xvivo Perfusion Ab Stock Profit Margin
XVIPF Stock | USD 41.23 0.77 1.83% |
Xvivo Perfusion AB fundamentals help investors to digest information that contributes to Xvivo Perfusion's financial success or failures. It also enables traders to predict the movement of Xvivo Pink Sheet. The fundamental analysis module provides a way to measure Xvivo Perfusion's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xvivo Perfusion pink sheet.
Xvivo |
Xvivo Perfusion AB Company Profit Margin Analysis
Xvivo Perfusion's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Xvivo Perfusion Profit Margin | 0.04 % |
Most of Xvivo Perfusion's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xvivo Perfusion AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Based on the latest financial disclosure, Xvivo Perfusion AB has a Profit Margin of 0.0444%. This is 100.4% lower than that of the Healthcare sector and 100.81% lower than that of the Medical Devices industry. The profit margin for all United States stocks is 103.5% lower than that of the firm.
Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
All Next | Launch Module |
Xvivo Fundamentals
Return On Equity | 0.0136 | |||
Return On Asset | 0.0057 | |||
Profit Margin | 0.04 % | |||
Current Valuation | 536.1 M | |||
Shares Outstanding | 29.83 M | |||
Shares Owned By Insiders | 12.25 % | |||
Shares Owned By Institutions | 54.00 % | |||
Price To Earning | 166.11 X | |||
Price To Book | 4.58 X | |||
Price To Sales | 16.90 X | |||
Revenue | 258.39 M | |||
Gross Profit | 296.96 M | |||
EBITDA | 39.2 M | |||
Net Income | 8.15 M | |||
Cash And Equivalents | 22.66 M | |||
Cash Per Share | 0.86 X | |||
Debt To Equity | 0 % | |||
Current Ratio | 6.48 X | |||
Book Value Per Share | 2.28 X | |||
Cash Flow From Operations | (12.06 M) | |||
Earnings Per Share | 0.10 X | |||
Number Of Employees | 133 | |||
Beta | 1.97 | |||
Market Capitalization | 674.8 M | |||
Total Asset | 1.54 B | |||
Net Asset | 1.54 B |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.